ABEONA THERAPEUTICS INC. Increase (Decrease) in Other Receivables
ABEONA THERAPEUTICS INC. (ABEO) reported Increase (Decrease) in Other Receivables of -$73.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for the quarter ending 2026-06-30 was -$14.00K, a 207.69% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for the quarter ending 2026-03-31 was -$59.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for the quarter ending 2025-12-31 was -$1.05M, a 2787.18% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for the quarter ending 2025-09-30 was -$14.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for fiscal 2025 was -$1.08M.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for fiscal 2024 was -$792.00K, a 138.80% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for fiscal 2023 was $2.04M, a 985.64% increase from fiscal 2022.
- ABEONA THERAPEUTICS INC. increase (decrease) in other receivables for fiscal 2022 was $188.00K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$73.00K 10-Q · filed 2026-08-13 | -$1.12M derived: sum of 3 quarters · filed 2026-08-13 | -$1.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$59.00K 10-Q · filed 2026-05-13 | -$1.11M derived: sum of 2 quarters · filed 2026-05-13 | -$1.12M derived: sum of 3 quarters · filed 2026-05-13 | -$1.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$1.06M derived: sum of 2 quarters · filed 2026-03-17 | -$1.05M derived: sum of 3 quarters · filed 2026-08-13 | -$1.08M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.00K derived: sum of 2 quarters · filed 2026-08-13 | -$36.00K 10-Q · filed 2025-11-12 | $3.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$22.00K 10-Q · filed 2026-08-13 | $17.00K derived: sum of 3 quarters · filed 2026-08-13 | -$10.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$35.00K 10-Q · filed 2026-05-13 | $4.00K derived: sum of 2 quarters · filed 2026-05-13 | -$23.00K derived: sum of 3 quarters · filed 2026-05-13 | -$575.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $12.00K derived: sum of 2 quarters · filed 2026-03-17 | -$540.00K derived: sum of 3 quarters · filed 2026-03-17 | -$792.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | -$27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$579.00K derived: sum of 2 quarters · filed 2025-11-12 | -$831.00K 10-Q · filed 2025-11-12 | -$811.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$552.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$804.00K 10-Q · filed 2025-08-14 | -$784.00K derived: sum of 3 quarters · filed 2025-08-14 | -$802.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$252.00K 10-Q · filed 2025-05-15 | -$232.00K derived: sum of 2 quarters · filed 2025-05-15 | -$250.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.71M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.97M derived: sum of 3 quarters · filed 2025-03-20 | $2.04M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.95M derived: sum of 2 quarters · filed 2024-11-14 | $2.02M 10-Q · filed 2024-11-14 | $1.16M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.04M 10-Q · filed 2024-08-12 | $1.18M derived: sum of 3 quarters · filed 2024-08-12 | $400.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $75.00K 10-Q · filed 2024-05-15 | -$784.00K derived: sum of 2 quarters · filed 2024-05-15 | -$1.56M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$859.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$1.64M derived: sum of 2 quarters · filed 2024-03-18 | $188.00K 10-K · filed 2024-03-18 | |
| 2022-09-30 | -$780.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.05M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $1.83M 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |